US equities |
NVDA $181.60 ▼-9.26% MU $656.39 ▼-17.46% AMD $404.40 ▼-17.26% TSLA $343.69 ▼-10.77% AAPL $344.17 ▼-1.53% SNDK $806.43 ▼-22.26% MSFT $535.93 ▼-3.58% AMZN $260.21 ▼-2.19%
FinancialContent

MiMedx Group, Inc - Common Stock (NQ:MDXG)

3.280 +0.080 (+2.50%)
Delayed Quote Updated: 4:00 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MiMedx Group, Inc - Common Stock

News headline image
RegenLab's Patent Setbacks Raise Questions Over $10 Million MiMedx Deal Ahead of Nasdaq IPO
Via Press Release Distribution Service
Topics Initial Public Offering Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ), Sanara MedTech Inc. (Nasdaq – SMTI), TriCo Bancshares (Nasdaq – TCBK)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself
From Biotech Insider
Via GlobeNewswire
News headline image
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
From World Street Intelligence
Via GlobeNewswire
News headline image
A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
Issued on behalf of Conexeu Sciences Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
From Pomerantz LLP
Via GlobeNewswire
News headline image
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
MDXG LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MDXG
From Rosen Law Firm
Via Business Wire
News headline image
MIMEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating MiMedx Group, Inc. on Behalf of MiMedx Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MiMedx Group (NASDAQ: MDXG) Reports Q1 2023 Financial Results Showing 21.7% Sales Growth
MiMedx Group, Inc. (NASDAQ: MDXG) is engaged as a biotechnology company that is focused as a placental biologics developer to 
Via Spotlight Growth
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
Via FinancialNewsMedia